Obalon Therapeutics, Inc.
OBLN · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $1,572 | $11,656 | $8,943 | $39,406 |
| - Cash | $693 | $3,905 | $14,055 | $21,187 |
| + Debt | $967 | $10,360 | $1,128 | $9,930 |
| Enterprise Value | $1,846 | $18,111 | -$3,984 | $28,149 |
| Revenue | $8,006 | $1,588 | $3,281 | $9,101 |
| % Growth | 404.2% | -51.6% | -63.9% | – |
| Gross Profit | $5,057 | $584 | $331 | $3,678 |
| % Margin | 63.2% | 36.8% | 10.1% | 40.4% |
| EBITDA | -$6,668 | -$11,491 | -$22,782 | -$36,799 |
| % Margin | -83.3% | -723.6% | -694.4% | -404.3% |
| Net Income | -$7,130 | -$12,334 | -$23,676 | -$37,380 |
| % Margin | -89.1% | -776.7% | -721.6% | -410.7% |
| EPS Diluted | -13.83 | -1.59 | -5.03 | -19.64 |
| % Growth | -769.8% | 68.4% | 74.4% | – |
| Operating Cash Flow | -$4,427 | -$10,409 | -$22,866 | -$29,432 |
| Capital Expenditures | $0 | -$171 | -$194 | -$1,282 |
| Free Cash Flow | -$4,427 | -$10,580 | -$23,060 | -$30,714 |